Role of human UGT2B10 in N-glucuronidation of tricyclic antidepressants, amitriptyline, imipramine, clomipramine, and trimipramine.
The role of human UDP glucuronosyltransferase (UGT) 2B10 in the N-glucuronidation of a number of tricyclic antidepressants was investigated and compared with that of UGT1A4 in both the Sf9 expressed system and human liver microsomes. The apparent K(m) (S(50)) values for the formation of quaternary N-glucuronides of amitriptyline, imipramine, clomipramine, and trimipramine were 2.60, 16.8, 14.4, and 11.2 microM in UGT2B10 and 448, 262, 112, and 258 microM in UGT1A4, respectively. The kinetics of amitriptyline and imipramine glucuronidation in human liver microsomes exhibited a biphasic character, where the high- and low-affinity components were in good agreement with our results in expressed UGT2B10 and UGT1A4, respectively. The kinetics of clomipramine and trimipramine glucuronidation in human liver microsomes were sigmoidal in nature, and the S(50) values were similar to those found for expressed UGT1A4. The in vitro clearances (CL(int) or CL(max)) were comparable between UGT2B10 and UGT1A4 for glucuronidation of imipramine, clomipramine, and trimipramine, whereas CL(int) of amitriptyline glucuronidation by UGT2B10 was more than 10-fold higher than that by UGT1A4. Nicotine was found to selectively inhibit UGT2B10 but not UGT1A4 activity. At a low tricyclic antidepressant concentration, nicotine inhibited their glucuronidation by 33 to 50% in human liver microsomes. Our results suggest that human UGT2B10 is a high-affinity enzyme for tricyclic antidepressant glucuronidation and is likely to be a major UGT isoform responsible for the glucuronidation of these drugs at therapeutic concentrations in vivo.
Zhou
Diansong
D
Clinical Pharmacology & DMPK, AstraZeneca Pharmaceuticals, 1800 Concord Pike, Wilmington, DE 19803, USA. diansong.zhou@astrazeneca.com
Guo
Jian
J
Linnenbach
Alban J
AJ
Booth-Genthe
Catherine L
CL
Grimm
Scott W
SW
D000639:Amitriptyline / Q000378:metabolism*; D000929:Antidepressive Agents, Tricyclic / Q000378:metabolism*; D055162:Biocatalysis / Q000187:drug effects; D002997:Clomipramine / Q000378:metabolism*; D004791:Enzyme Inhibitors / Q000494:pharmacology; D020723:Glucuronic Acid / Q000378:metabolism*; D020719:Glucuronides / Q000378:metabolism; D014453:Glucuronosyltransferase / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism*; D006801:Humans; D007099:Imipramine / Q000378:metabolism*; D007700:Kinetics; D008862:Microsomes, Liver / Q000201:enzymology; D009538:Nicotine / Q000494:pharmacology; D011994:Recombinant Proteins / Q000378:metabolism; D012502:Sapogenins / Q000494:pharmacology; D014299:Trimipramine / Q000378:metabolism*; D000099148:UGT1A1 Enzyme
D000639:Amitriptyline; D000929:Antidepressive Agents, Tricyclic; D002997:Clomipramine; D004791:Enzyme Inhibitors; D020723:Glucuronic Acid; D020719:Glucuronides; D014453:Glucuronosyltransferase; D007099:Imipramine; D009538:Nicotine; D011994:Recombinant Proteins; D012502:Sapogenins; D014299:Trimipramine; D000099148:UGT1A1 Enzyme; C019787:bilirubin glucuronoside glucuronosyltransferase; C007908:hecogenin; C552162:UGT2B10 protein, human